ArticleJTO clinical and research reports2022
Successful Tepotinib Challenge After Capmatinib-Induced Interstitial Lung Disease in a Patient With Lung Adenocarcinoma Harboring
Article in JTO clinical and research reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 16 citations in OpenAlex.
- Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.Cancer science · 2024Trial
- Management of Adverse Events Associated with MET TKIs in Patients with Advanced NSCLC: A Podcast Discussion.Targeted oncology · 2026Article
- Successful Tepotinib Rechallenge after Tepotinib-induced Adverse Events Following Pembrolizumab Failure in a Case of Non-small Cell Lung Carcinoma with MET Exon 14 Skipping.Internal medicine (Tokyo, Japan) · 2026Article
- Targeted Therapy-Induced Interstitial Lung Disease in NSCLC: Mechanisms, Clinical Signatures, and a Precision Medicine Roadmap.Drug design, development and therapy · 2026Review
- Challenges and Limitations of Sequential MET-TKI Therapy in METex14- Positive NSCLC With a Focus on Non-ILD Toxicities: A Case Report.Cancer reports (Hoboken, N.J.) · 2026Article
- Tepotinib-induced interstitial lung disease in a patient with adenosquamous lung carcinoma.Respiratory medicine case reports · 2026Article
- Targeted therapies in lung cancer: personalizing treatment across the age spectrum.Frontiers in oncology · 2026Review
- Tyrosine Kinase Inhibitors and Interstitial Lung Disease: A Disproportionality Analysis Using the European Post-marketing EudraVigilance Database.Drugs - real world outcomes · 2025Article
- Mesenchymal-epithelial Transition Exon 14-skipping Mutation-positive Invasive Mucinous Adenocarcinoma of the Lung: First Case Treated with Mesenchymal-epithelial Transition-tyrosine Kinase Inhibitors.Internal medicine (Tokyo, Japan) · 2024Article
- Effective treatment ofAME case reports · 2024Article
- Salvage Therapy With Selpercatinib forJTO clinical and research reports · 2023Article
- Capmatinib‑associated interstitial lung disease in a patient with lung adenocarcinoma harboring a skipping mutation of mesenchymal‑epithelial transition exon 14: A case report.Oncology letters · 2023Article
- Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management.Signal transduction and targeted therapy · 2023Review
- Transient asymptomatic pulmonary opacities in a patient with MET exon 14 skipping non-small cell lung cancer: A case report.Thoracic cancer · 2023Article
- Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives.Cancer management and research · 2023Review
- Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report.International journal of molecular sciences · 2022Article
- Interstitial Lung Disease due to Tepotinib after Durvalumab in a Patient with Lung Adenocarcinoma Harbouring MET Exon 14 Skipping Mutation: A Case Report.Case reports in oncologyArticle
- Complete Response on Larotrectinib in NTRK2 Fusion-Positive Non-Small Cell Lung Cancer.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MET tyrosine kinase inhibitors, capmatinib and tepotinib, have been recently introduced for the treatment of advanced NSCLC with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.